LivingGLP1
Study S001837

Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial

ClinicalTrials.gov record

Registration

Registration
NCT07284511
Acronym
TZP
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2; PHASE3
Masking
NONE
Status
RECRUITING
Enrollment
105
Start
2026-05-19
Primary completion
2028-01
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions
Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus
Interventions
DRUG:Tirzepatide; DEVICE:Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM); BEHAVIORAL:Carbohydrate Counting; BEHAVIORAL:No Meal Announcement
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • Daytime Time-in-Range [During the final 6 weeks of the study]

Linked records (11)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0012082Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes.
Snell-Bergeon JK, Diabetes technology & therapeutics
2025Nonrandomized studyPMID 39745353DOIregistry reference BACKGROUND:39745353
R0017571Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity.
Rivera Gutierrez R, Mayo Clinic proceedings
2025Nonrandomized studyPMID 39601745DOIregistry reference BACKGROUND:39601745
R0017835Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
Pasqua MR, Nature medicine
2025Randomized trialPMID 39794615DOIregistry reference BACKGROUND:39794615
R0018894Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.
Karakus KE, Diabetes therapy : research, treatment and education of diabetes and related disorders
2024OtherPMID 38743306DOIregistry reference BACKGROUND:38743306
R0013656Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, The New England journal of medicine
2021Randomized trialPMID 34170647DOIregistry reference BACKGROUND:34170647
R0019465Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS, Diabetes & metabolism
2020Randomized trialPMID 31539622DOIregistry reference BACKGROUND:31539622
R0018537Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Lancet (London, England)
2019Randomized trialPMID 31189511DOIregistry reference BACKGROUND:31189511
R0020680Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Ahmann AJ, Diabetes care
2018Randomized trialPMID 29246950DOIregistry reference BACKGROUND:29246950
R0022507Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes.
Saisho Y, International journal of environmental research and public health
2018Narrative reviewPMID 29747423DOIregistry reference BACKGROUND:29747423
R0022060Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27295427DOIregistry reference BACKGROUND:27295427
R0022278Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27633186DOIregistry reference BACKGROUND:27633186